Basel, 11 June 2019 Changes in Roche’s Board of Directors and Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Peter Voser (61), a member of the Board of Directors of Roche Holding Ltd since 2011, has decided to step down as a member of the Board of Directors of Roche at... Read more
Basel, 10 June 2019 Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that they have each received a request for additional... Read more
Basel, 04 June 2019 Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions as determined by... Read more
Basel, 03 June 2019 Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Roche data from 17 breast cancer abstracts presented at this year’s meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative breast cancer at the second... Read more
Basel, 02 June 2019 Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche (SIX: RO,... Read more
Basel, 31 May 2019 Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of... Read more
VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody IHC staining of lung adenocarcinoma tissue Roche’s VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market The biomarker may provide a cost-effective and efficient means to initially identify elevated ROS1 protein expression in cancer ROS1-positive cancer... Read more
Basel, 16 May 2019 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia... Read more
Basel, 16 May 2019 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) fusions, including those in the central nervous... Read more
Basel, 14 May 2019 New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis... Read more